L2 Asset Management LLC Buys Shares of 952 Regeneron Pharmaceuticals, Inc. $REGN

L2 Asset Management LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 952 shares of the biopharmaceutical company’s stock, valued at approximately $594,000.

A number of other large investors have also made changes to their positions in REGN. Western Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals during the first quarter valued at approximately $26,000. SHP Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $26,000. Titan Wealth CI Ltd bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $29,000. Kemnay Advisory Services Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $31,000. Finally, Birchwood Financial Partners Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $32,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Piper Sandler lowered their target price on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research report on Thursday, July 9th. Royal Bank Of Canada upped their price target on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. Leerink Partners raised their price objective on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a research note on Monday, August 17th. JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $801.70.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $320,000.00. Following the transaction, the director owned 603 shares of the company’s stock, valued at approximately $482,400. The trade was a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock worth $1,090,030 in the last 90 days. 6.97% of the stock is currently owned by corporate insiders.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: An analysis titled “Regeneron: Why I Still See Upside After the Rally” reflects a continued bullish view of REGN’s long-term prospects following its recent advance. Regeneron: Why I Still See Upside After the Rally
• Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day short-interest ratio. However, the figures appear incomplete or erroneous, making them unsuitable as a meaningful trading signal.
• Negative Sentiment: Several law firms publicized a securities-fraud class action tied to Regeneron’s Phase 3 melanoma-therapy trial failure. The trial disclosure reportedly triggered a sharp selloff and erased approximately $11 billion in market value; the lawsuit alleges investors were harmed by inadequate or misleading disclosures. A September 14, 2026 deadline applies to investors seeking lead-plaintiff status. Notices were issued by Hagens Berman, Pomerantz, SueWallSt, and Portnoy Law.
• Negative Sentiment: Additional law firms, including Faruqi & Faruqi, Schall Brown & Schwartz, and Levi & Korsinsky, reiterated the pending litigation and encouraged affected shareholders to participate. The repeated announcements increase near-term legal and reputational overhang, although they do not represent new operating developments. Faruqi & Faruqi notice

Regeneron Pharmaceuticals Trading Up 0.6%

REGN stock opened at $833.56 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $847.00. The business has a 50 day simple moving average of $705.74 and a two-hundred day simple moving average of $717.35. The company has a market capitalization of $85.82 billion, a price-to-earnings ratio of 20.60, a PEG ratio of 1.41 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same quarter last year, the business posted $12.81 earnings per share. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.